Latest Breaking News On - Division of urologic oncology - Page 1 : comparemela.com

Limmi adds Oncobiomix as customer of Disease Insights Platform, powering microbiome-based risk prediction for cancer

Limmi adds Oncobiomix as customer of Disease Insights Platform, powering microbiome-based risk prediction for cancer
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United statesBryan ivoryTechnology officerDepartment of urologyDivision of urologic oncologyDisease insights platformMichael lissUrologic oncologyTexas health science center sanLimmi presidentChief technology

Dr Singer on the Safety of Perioperative Nivolumab and Cabozantinib in RCC

Eric A. Singer, MD, discusses the safety of perioperative nivolumab and cabozantinib in patients with metastatic clear cell renal cell carcinoma.

United statesDivision of urologic oncologyAmerican urological association annual meetingOhio state university comprehensive cancer centerOhio state university wexner medical centerUrologic oncologyUrological association annual meetingThe ohio state university comprehensive cancer center james hospital amp solove research instituteUsuccc jamesGenitourinary cancersOnclive tv

Pembrolizumab Could Delay Radical Cystectomy in BCG-unresponsive, High-risk NMIBC

Eric A. Singer, MD, discusses the findings from cohort B of KEYNOTE-057 and explains why systemic therapy with pembrolizumab could be beneficial for patients with Bacillus Calmette-Guérin–unresponsive, high-risk, papillary-only non–muscle invasive bladder cancer who hope to avoid radical cystectomy.

United statesOhio state universityAstellas medivationOhio state university comprehensive cancer centerOhio state university wexner medical centerAmerican urological associationDivision of urologic oncologyBacillus calmette guUrological associationAnnual meetingUrologic oncologyMerck sharpBacillus calmette guerinKeynote 057 trialBacillus calmette guérinNon muscle invasive bladder cancer

Dr Singer on Systemic Pembrolizumab Monotherapy in BCG-unresponsive High-Risk NMIBC

Eric A. Singer, MD, discusses the use of systemic pembrolizumab monotherapy in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle invasive bladder cancer.

Ohio state university comprehensive cancer centerDivision of urologic oncologyOhio state university wexner medical centerUrologic oncologyBacillus calmette guPembrolizumab monotherapyErica singerBacillus calmette guérin bcg unresponsiveHigh risk non muscle invasive bladder cancer

Pembrolizumab Monotherapy Demonstrates Clinical Efficacy in High-risk NMIBC

Treatment with pembrolizumab monotherapy resulted in stable long-term disease-free survival rates in patients with Bacillus Calmette-Guérin–unresponsive, high-risk non–muscle-invasive bladder cancer.

United statesOhio state university comprehensive cancer centerAmerican urological association annual meetingOhio state university wexner medical centerDivision of urologic oncologyBacillus calmette guUrological association annualUrologic oncologyOhio state university comprehensive cancerPembrolizumab monotherapyPatients with bacillus calmette guérin unresponsiveHigh risk non muscle invasive bladder cancerKeynote 057 trialErica singerThe ohio state university wexner medical centerThe ohio state university comprehensive cancer center